Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy
Authors:
- Perry B. HackettPHPerry B. Hackett
- Timothy K. StarrTSTimothy K. Starr
- Laurence J.N. CooperLCLaurence J.N. Cooper
- 1 January 2015
- book chapter
- Published by Elsevier
- p. 65-83
Abstract
No abstract availableThis publication has 129 references indexed in Scilit:
- Human Transposon TectonicsCell, 2012
- Precision Editing of Large Animal Genomes2012
- Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trialsEMBO Molecular Medicine, 2011
- DDE transposases: Structural similarity and diversityAdvanced Drug Delivery Reviews, 2010
- LINE-1 Retrotransposition Activity in Human GenomesCell, 2010
- Natural Mutagenesis of Human Genomes by Endogenous RetrotransposonsCell, 2010
- Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell diseaseJournal of Molecular Medicine, 2010
- Systemic Correction of Storage Disease in MPS I NOD/SCID Mice Using the Sleeping Beauty Transposon SystemMolecular Therapy, 2009
- Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidosesThe Journal of Gene Medicine, 2007
- Initial sequencing and analysis of the human genomeNature, 2001